Product logins

Find logins to all Clarivate products below.


Exdensur (depemokimab)

Learn how Exdensur is changing the asthma landscape.

Latest news

EC approves Exdensur for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP) EC approves Exdensur for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP)
February 17, 2026
EC approves Exdensur for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP)
The approval covers two indications: (1) add-on maintenance treatment for severe asthma with type 2 inflammation characterized by blood eosinophil count in adults and adolescents ≥12 years and (2) add-on therapy with intranasal corticosteroids to treat adult patients with severe CRSwNP. The approval was based on data from the phase 3 SWIFT and ANCHOR trials, and this positions Exdensur as the first ultra-long-acting biologic to treat respiratory diseases in the E.U.
Japan MHLW approves Exdensur for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Japan MHLW approves Exdensur for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
January 6, 2026
Japan MHLW approves Exdensur for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Exdensur was approved to treat bronchial asthma and CRSwNP based on results from the phase 3 SWIFT and ANCHOR trials. This marks its third regulatory approval after approvals from the U.S. FDA and U.K. MHRA and makes it the first ultra-long-acting biologic in Japan to treat severe asthma and CRSwNP.
chevron_left
chevron_right

What is depemokimab (Exdensur) and what sets it apart

Exdensur is the first approved ultra-long-acting biologic with a six-month dosing schedule for severe asthma, which could provide greater convenience over currently available interleukin (IL)-5 inhibitors that require monthly or bimonthly dosing.

Exdensur’s extended half-life could provide sustained inhibition of broad inflammatory functions, including suppression of type 2 inflammation, and is being investigated in multiple type 2 inflammatory conditions. Positive top-line data support its efficacy for severe asthma as well as chronic rhinosinusitis with nasal polyps (CRSwNP) over a one-year period.

About Exdensur

  • Company: GSK
  • Type: Monoclonal antibody targeting IL-5
  • Usage: Twice-yearly subcutaneous administration to treat asthma in adolescents and adults
    Also being evaluated for other IL-5-mediated diseases including CRSwNP, eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome
  • When will depemokimab be available?
    Expected launch 2026: Japan, United States
    Expected launch 2027: European Union

Exdensur sales and success forecasts

$510m
expected sales in the G7 markets in 2031
95%
probability of success for Exdensur in the European Union

I think depemokimab lasting for six months is very promising. It will allow us to talk about asthma remission because the patient won’t need to come to the hospital very often.

Allergist Spain

Drugs in the 2026 list